BackgroundChildren with relapsed/refractory (R/R) neuroblastoma are at risk for poor outcomes due to resistant disease. Naxitamab is an anti-glycolipid disialoganglioside (GD2) monoclonal antibody approved by the Food and Drug Administration for the treatment ... ...
